Faga Daniel 4

What Happened On April 20, 2026, Daniel Faga (President, CEO and Director of AnaptysBio) had multiple derivative option positions adjusted: the filing shows paired dispositions to the issuer and re-grants (codes D and A) for a total of 1,035,941 optioned shares (each line at $0.00). These entries reflect an administrative adjustment tied to a corporate separation/spin-off, not an open‑market sale or purchase — no cash was received or paid.

Key Details

• Transaction date: April 20, 2026; Form 4 filed April 22, 2026 (timely within the normal 2‑business‑day window).
• Actions reported: multiple dispositions to issuer (D) and corresponding grants/awards (A) — all at $0.00 per share (derivative adjustments).
• Total options affected (sum of reported lines): 1,035,941 optioned shares cancelled and reissued in equal amounts.
• Shares owned after transaction: not disclosed in the supplied filing excerpt.
• Relevant footnote F1: adjustments were made pursuant to a pro rata distribution under the Separation and Distribution Agreement with First Tracks — each outstanding option was adjusted into an option for First Tracks shares and an option for AnaptysBio shares, resulting in the reported acquisitions of AnaptysBio options.
• Vesting notes (F2–F6): one option is fully vested (F2); others have time‑based vesting schedules (25% at initial date then monthly 1/48th vesting) with various start dates through 2027 (see F3–F6).

Context These are derivative/option adjustments tied to a corporate separation rather than routine insider buying or selling. Because the transactions are technical re‑allocations (no cash exchange, no open‑market trades), they do not directly signal insider buying or selling sentiment. Vesting schedules noted in the filing indicate some options are already vested while others vest over time, which affects when the holder could potentially convert options to shares.